NEW YORK – Direct-to-consumer custom probiotics and gut health company Sun Genomics said on Monday that it has closed an $8.7 million Series A funding round.
The round was led by Pangaea Ventures, with additional investments from Danone Manifesto Ventures, SOSV, Human Longevity, and Nascita Ventures. Pangaea Ventures Founding General Partner Chris Erickson has also joined Sun Genomics' board of directors.